Resistant mechanisms to afatinib in non-small cell lung cancer with EGFR mutations

Resistant mechanisms to afatinib in non-small cell lung cancer with EGFR mutations - Resistant mechanisms to afatinib

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024476

Enrollment

Registered

2016-10-19

Start date

2016-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

afatinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histologically or cytologically confirmed non-small cell lung cancer patients 2)Patients with EGFR mutation 3)Patients treated with afatinib, or who have a planned treatment with afatinib 4)Blood sampling at resistance to afatinib 5)Patients who are considered to survive for more than 3 months 6)Written informed consent 7)Patients aged 20 years or older

Exclusion criteria

Exclusion criteria: 1)Patients with active double or multifocal cancers 2)Patients whose lesions are hard to evaluate

Design outcomes

Primary

Measure	Time frame
Detection of T790M mutation in cfDNA	—

Countries

Japan

Contacts

Public ContactHideharu Kimura

Kanazawa University Hospital Respiratory Medicine

hkimura3625@staff.kanazawa-u.ac.jp076-265-2273

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026